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INTRODUCTION
Since Schaldenbrand and Appelman applied the term ‘‘stro-
mal tumor’’ to collectively refer to a group of mesenchymal
neoplasms of gastrointestinal tract in 1984 (1), there was con-
siderable confusion with regards to the classification of the
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Current Trends in the Epidemiological and Pathological Characteristics
of Gastrointestinal Stromal Tumors in Korea, 2003-2004
Despite remarkable progress in understanding and treating gastrointestinal stromal
tumors (GISTs) during the past two decades, the pathological characteristics of GISTs
have not been made clear yet. Furthermore, concrete diagnostic criteria of malig-
nant GISTs are still uncertain. We collected pathology reports of 1,227 GISTs from
38 hospitals in Korea between 2003 and 2004 and evaluated the efficacy of the NIH
and AFIP classification schemes as well as the prognostic factors among pathologic
findings. The incidence of GISTs in Korea is about 1.6 to 2.2 patients per 100,000.
Extra-gastrointestinal GISTs (10.1%) are more common in Korea than in Western
countries. In univariate analysis, gender, age, tumor location, size, mitosis, tumor
necrosis, vascular and mucosal invasions, histologic type, CD34 and s-100 protein
expression, and classifications by the NIH and AFIP criteria were found to be signif-
icantly correlated with patient’s survival. However, the primary tumor location, stage
and classification of the AFIP criteria were prognostically significant in predicting
patient’s survival in multivariate analysis. The GIST classification based on original
tumor location, size, and mitosis is more efficient than the NIH criteria in predicting
patient’s survival, but the mechanism still needs to be clarified through future studies. 
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was eliminated, and clarification and restructuring became
reliable with the introduction of the KIT protein expression
in gastrointestinal stromal tumors (GISTs). Because most
GISTs have an activating mutation in the c-kit proto-onco-
gene that leads to expression of KIT protein, the immunohis-
tochemical stain for the KIT (CD117) is now used by pathol-
ogists to distinguish GISTs from non-GISTs mesenchymal
tumors in gastrointestinal tract (2, 3). This was the chief rea-
son why epidemiologic studies of GISTs in Korea were unre-
liable before the 2000s. Based on the biological characteris-
tics of this tumor, treatment with KIT/PDGFRa tyrosine
kinase inhibitors, such as imatinib, can lead to complete or
partial remission when the tumor is unresectable or in a meta-
static setting (4). Therefore, accurate pathological diagnosis
is mandatory for proper treatment of patients with mesenchy-
mal tumors of gastrointestinal tract. Recently, protein kinase
C theta (PKC-q) (5) and DOG1 (6) over-expression in addi-
tion to mutation analysis of the c-kit and PDGFRa (7) were
described as diagnostic markers for GISTs. 
Despite remarkable progress in understanding and treat-
ing GISTs, pathologists still have a difficulty in classifying
GISTs because of a lack of concrete diagnostic evidence to
predict patient’s prognosis. The incidence of GIST varies as
reported in different studies from different countries (8-11).
Gender, race, and location distribution of GISTs are also uncer-
tain. Furthermore, there is no agreement on prognostic fac-
tors of GISTs. In 2002, National Institute of Health (NIH)
reported a consensus approach in diagnosing GISTs (2). The
efficacy of the NIH criteria had been discussed, although it
is commonly used in clinical setting. Recently, new diagnos-
tic criteria in predicting prognosis of GISTs have been pro-
posed by Miettinen et al in the Armed Forces Institutes of
Pathology (AFIP) (12, 13). It has caused some confusion with
regards to the terminology used in cancer registration, and
it became difficult to identify the actual incidence of malig-
nant GISTs. 
To create informative and standardized pathological reports
of GIST, we need to evaluate contents of pathology reports
collected nationwide and to identify significant factors that
predict the prognosis. We previously analyzed pathological
characteristics of GISTs and described the pitfalls in interpre-
tation of KIT expression as well as pathological diagnosis of
GISTs (14) through a nationwide study of GISTs in Korea
from 2001 to 2002 (14). One outstanding phenomena found
in previous research was that small intestinal and esophageal
GISTs were more common in Korea than in Western coun-
tries, but the incidence and prognostic factors of GISTs in
Korea have not been made clear yet.
In this study, we firstly described the population based inci-
dence of GIST in Korea. Then, we identified pathological
characteristics that should be mentioned in pathology reports
of GISTs to predict patient’s prognosis and evaluated the effi-
cacy of the NIH and AFIP classification criteria. Data obtained
from this nationwide multi-institutional study may provide
an insight in the epidemiological characteristics and prognos-
tic stratification of GISTs in Korea.
MATERIALS AND METHODS
Population based incidence of GISTs in Korea: Review
the data of the National Cancer Institute Registry
To identify the population based incidence and trends in
epidemiology of malignant GISTs in Korea, we reviewed all
data collected by the Korean National Cancer Institute (NCI)
and correlated the data with the population information of
the Korea National Statistical Office. All tumors in the NCI
Registry were identified by the International Classification
of Disease for Oncology (ICD-O), 3rd edition, from the World
Health Organization (WHO). 
Reviewing pathology reports from 38 hospitals in Korea,
2003-2004
For survival analysis, we retrospectively collected nation-
wide multi-institutional data of pathology reports diagnosed
as GISTs not only in gastrointestinal tract but also in extra-
gastrointestinal areas from 2003 to 2004. 
The list of participant hospitals were as follows: Sungkyun-
kwan University Seoul Samsung Medical Center and Kang-
buk Samsung Medical Center, Asan Medical Center, Seoul
National University Hospital and Bundang Hospital and
Boramae Hospital, Yonsei University Severance Hospital and
Kangnam Severance Hospital and Wonju Christian Hospi-
tal, Chonnam University Hospital, Ewha Woman’s Univer-
sity Hospital, Ajou University Hospital, Yeungnam Univer-
sity Hospital, Inje University Seoul Paik Hospital, Busan Paik
Hospital and Ilsan Paik Hospital, The Catholic University of
Korea Seoul St. Mary’s Hospital, Uijeongbu St. Mary’s Hos-
pital and St. Vincent Hospital, National Cancer Center, Dong-
A University Hospital, Korea University Seoul Hospital and
Ansan Hospital, Choongnam University Hospital, Daegu
Catholic University Hospital, Soonchunhyang University
Seoul Hospital and Bucheon Hospital, Inha University Hos-
pital, Busan University Hospital, Choongbuk University Hos-
pital, Eulji University Hospital, Chonbuk University Hos-
pital, Gosin University Hospital, Hallym University Hos-
pital, Daegu Fatima Hospital, Kyunghee University Hospi-
tal, CHA Medical School Hospital, and Busan Baptist Hos-
pital. Institutional Review Board of Sungkyunkwan Univer-
sity Kangbuk Samsung Medical Center gave a permission
for this research (C 0847).
Data collected from pathology reports 
We collected data of age, gender, primary tumor location,
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tochemical findings (c-kit, desmin, actin, s-100, CD34) in
patients, if they were described. Then, we evaluated the con-
tents of pathology reports. GIST locations were categorized
into esophagus, stomach, small intestine, large intestine, and
extra-gastrointestinal areas. Follow-up data were taken from
the Korea National Statistical Office. All the data were em-
ployed to perform an anonymous and aggregate statistical
analysis.
To estimate prognostic significance of the classification
schemes of GISTs, each tumor was re-classified the basis of
descriptions in the pathology reports. The used diagnostic
criteria were those proposed by the National Institutes of
Health (NIH) GIST Workshop (2001) and the AFIP (2002).
The NIH criteria includes four risk groups; very low risk (<2
cm and <5 mitoses/50 HPF), low risk (2-5 cm and <5 mito-
ses/50 HPF), intermediate risk (<5 cm and 6-10 mitoses/50
HPF or 5-10 cm and <5 mitoses/50 HPF), and high risk (>5
cm and >5 mitoses/50 HPF or >10 cm regardless of mitot-
ic activity or >10 mitoses/50 HPF regardless of the tumor
size). On the other hand, the AFIP criteria (2002) includes
three groups; benign (stomach ≤5 cm and <5/50 HPF; intes-
tine ≤2 cm and <5/50 HPF), uncertain or low malignant
potential (stomach >5 cm and ≤10 cm and <5/50 HPF;
intestine >2 cm but ≤5 cm and <5/50 HPF), and malig-
nant (stomach >10 cm or ≥5/50 HPF; intestine >5 cm or
≥5/50 HPF).
Statistical analysis
Data were presented as numbers (%) for categorical vari-
ables. To estimate the association between eligible variables
and mean survival time, the Kaplan-Meier test was applied
together with the log-rank test to compare various groups.
We conducted the Cox proportional hazard regression anal-
ysis to estimate hazard risk ratios and 95% confidence inter-
vals (CI) of the possible risk factors for survival after adjust-
ment in age and sex. The SPSS (version 13.0) was used for
statistical analyses. A P value of <0.05 was considered statis-
tically significant.
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Year
Mid-year 
population
All malignant
tumors
(crude inci-
dence rate)
Malignant
GISTs
(crude inci-
dence rate)
1999 46,616,677 101,032 (217.0) 12 (0.02)
2000 47,008,111 101,772 (217.0) 32 (0.07)
2001 47,357,362 111,234 (241.0) 82 (0.17)
2002 48,125,751 117,089 (243.9) 113 (0.24)
2003 48,308,396 124,209 (257.1) 291 (0.60)
2004 48,485,321 132,005 (272.3) 336 (0.69)
2005 48,683,049 142,610 (292.9) 367 (0.75)
Table 1. Changes in incidence of malignant GISTs compared
with all malignant tumors from 1999 to 2005: Data of Korean
National Cancer Registry
NA, Not available; Number in parenthesis is percentage.
Number of 
subjected (%)
Subgroups Variables
Age 1,227 (100.0) <60 (43.7) ≥60 (56.3) 11-86 (57.85±
12.62 yr old)
Gender 1,227 (100.0) Male (52.3) Female (47.7)
Size (cm) 1,129 (92.0) <2 (23.9) 2-4.9 (34.9) 5-9.9 (26.7) ≥10 (14.5)
Location 1,223 (99.7) Esophagus  Stomach Small intestine  Large intestine  Extra-gastro-
(1.2) (59.9) (23.2) (5.8) intestinal (10.1)
Mitosis 1,125 (91.7) <5 (57.9) ≥5 (42.1)
Stage 1,122 (91.4) Confined to organs  Invasion into adjacent  Distant metastasis  Recurrences
(76.7) organs (4.3) (9.0) (1.5)
Diagnosis by  1,140 (92.9) Benign (36.6) Uncertain  Malignancy (40.9) NA (7.1)
AFIP (2002) malignancy (15.4)
Diagnosis by NIH 1,125 (91.7) Very low (16.1) Low (27.7) Intermediate (17.4) High (27.4) Metastatic, 
recurrences (3.1)
Necrosis 264 (21.5) - (54.5) + (45.5)
Vessel Invasion 104 ( 8.5) - (91.3) + (8.7)
Mucosal Invasion 145 (11.8) - (60.7) + (39.3)
Histologic type 805 (65.6) Spindle (81.7) Epithelioid (6.3) Mixed (7.6) Other (4.3)
C-Kit 1,112 (90.6) - (3.8) + (96.2)
CD34 971 (79.1) - (18.8) + (81.2)
Actin 1,013 (82.6) - (64.2) + (35.8)
S-100 988 (80.5) - (83.7) + (16.3)
Table 2. Characteristics of GISTs diagnosed during 2003-2004: A nationwide dataRESULTS
Population based incidence of malignant GISTs in Korea 
There were 1,233 cases of malignant GISTs in the Nation-
al Cancer Institute (NCI) Registry from 1999 to 2005 (Table
1). Table 1 shows the incidence of malignant GISTs in com-
parison with all malignant tumors registered. There was a
big shift in GISTs incidences between 1999 and 2002 and
also from 2003 to 2005, while the incidence of all malignant
tumors was almost the same during the same time. Extra-gas-
trointestinal GISTs (8.3-8.7%) showed to be more common
than esophageal GISTs (0.7-1.1%). 
Characteristics of GISTs: nationwide collection from 
38 hospitals in Korea during 2003-2004
We collected 1,227 pathology reports from the 38 partic-
ipating hospitals from January 1, 2003 to December 31, 2004.
The characteristics of GISTs and contents of pathology reports
collected nationwide are shown in Table 2. The range of pati-
ent age was from 11 to 86 yr old (mean 57.83±12.62); 5
(0.4%) was in their 1st decade, 20 (1.6%) in 2nd, 87 (7.1%)
in 3rd, 200 (16.3%) in 4th, 302 (24.6%) in 5th, 382 (31.1%)
in 6th, 210 (17.1%) in 7th, and 21 (1.7%) in 8th. Male to
female ratio was 1 to 1.7. The most common location of tumor
was stomach. Extra-gastrointestinal locations were omentum
and mesentery (45.1%). Then, pelvis (9.8%), intra-abdomi-
nal (34.3%), retroperitoneum (3.9%), abdominal wall (3.9%),
and pancreas (3%) were found to be occurring sites of extra-
gastrointestinal GISTs. Liver (46), lymph node (9), bone, lung,
spleen, diaphragm, and so on were found to be metastatic sites
of GISTs. One hundred cases (8.2%: 3 in the esophagus, 85
in the stomach, 8 in the small intestine, 1 in the large intes-
tine and 1 in extra-gastrointestinal) were incidentally found
during operations for other diseases. More than 90% of the
tumors showed the result of c-kit immunostain in patholo-
gy reports in contrast with CD34, actin and s-100 protein
in which about 80% were found to have. Almost all GISTs,
which provided the results of immunostains, were c-kit posi-
tive (96.2%). The relationship between tumor location and
malignancy, defined by variable criteria are presented in Tables
3-5. 
The incidence of gastric GIST was slightly increased in ages
older than 60 yr, in contrast to decreases in the incidence of
the small intestinal GISTs. However, the location of tumor
was not significantly related with patient’s age (P=0.083). In
general, it showed male preponderance. Esophageal, large
intestinal, and extra-gastrointestinal GISTs were more com-
mon in males than in females, but gastric GISTs were more
common in females (P=0.027).
In the collected pathology reports, GISTs were classified
by the NIH criteria (55.4%), the AFIP criteria (41.7%), and
other (2.9%). To compare the prognostic value of the diag-
nostic criteria, we re-classified each GIST by the NIH crite-
ria as well as the AFIP criteria based on the descriptions in
the pathology reports, including tumor, size, location, and
mitosis (Tables 3, 4). About half of the GISTs in our study
were malignant according to the AFIP criteria. Benign tumors
were common in stomach in contrast to malignant tumors
which were more common in intestinal and extra-gastroin-
testinal areas (P=0.000). High risk tumors, as classified by
the NIH criteria, were also more common in the small and
large intestinal and extra-gastrointestinal locations than in
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AFIP criteria
Number of patients (%) in
Extra- 
gastrointestinal Total Large intestine Small intestine Stomach Esophagus
Benign 6 (46.2) 392 (57.6) 35 (12.7) 10 (16.4) 4 (4.5) 447 (40.0)
Uncertain malignancy 5 (38.5) 100 (14.7) 72 (26.2) 6 (9.8) 6 (6.8) 189 (16.9)
Malignancy 2 (15.4) 188 (27.6) 168 (61.1) 45 (73.8) 78 (88.6) 481 (43.1)
Total 13 (100) 680 (100) 275 (100) 61 (100) 88 (100) 1,117 (100)
Table 3. The relationship between tumor location and malignancy, defined by the AFIP criteria
NIH criteria
Number of patients (%) in
Extra- 
gastrointestinal Total Large intestine Small intestine Stomach Esophagus
Very low risk 6 (46.2) 158 (23.5) 22 (8.1) 7 (11.9) 3 (3.5) 196 (17.8)
Low risk 0 (0.0) 242 (36.0) 83 (30.7) 8 (13.6) 4 (4.7) 337 (30.6)
Intermediate risk 5 (38.5) 125 (18.6) 56 (20.7) 11 (18.6) 17 (19.8) 214 (19.5)
High risk 2 (15.4) 147 (21.9) 109 (40.4) 33 (55.9) 62 (72.1) 353 (32.1)
Total 13 (100) 672 (100) 270 (100) 59 (100) 86 (100) 1,100 (100)
Table 4. The relationship between tumor location and risk group, defined by the NIH criteriastomach (P=0.001). Most of extra-gastrointestinal tumors
were malignant (88.6%) or high risk (72.1%). We also re-
classified GISTs into eight groups based on tumor size and
mitosis according to a new classification by Miettinen and
Lastosa 2006 (15) (Table 5). However, statistical analysis was
not available due to the small number of tumors in some cat-
egories. As shown in Table 5, tumor size was correlated with
mitosis. In the group with mitotically active GISTs, gastric
tumors tend to be small in size compared with tumors in intes-
tine, extra-gastrointestinal areas, and esophagus. The descrip-
tion of tumor necrosis, vessel and mucosal invasions, and his-
tologic type were found only in 21.5%, 8.5%, 11.8%, and
65.6% of pathology reports collected for this study, respec-
tively. 
Survival analysis
During the follow-up study period, we found that 102
patients died as a result of GISTs. Most GISTs, which caused
mortality, were malignant (80.4%) or high risk (66.7%). How-
ever, 1.8% of benign or uncertain malignant tumors and 6.9%
of very low risk, low risk or intermediate tumors led to mor-
tality. In the same risk group by the NIH criteria, the inci-
dence of patients, who died of the diseases, was higher in small
intestinal and extra-gastrointestinal GISTs than gastric ones.
The malignant GISTs by the AFIP criteria also demonstrat-
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Number of patients (%) in tumor size of 
2-4.9 cm <2 cm 5-9.9 cm ≥10 cm
Total
Mitosis <5
Eosphagus 7 (70.0) 1 (10.0) 2 (20.0) 0 (0.0) 10 (100)
Stomach 169 (36.0) 190 (40.4) 87 (18.5) 24 (5.1) 470 (100)
Small intestine 18 (12.9) 59 (42.1) 45 (32.1) 18 (12.9) 140 (100)
Large intestine 13 (39.4) 9 (27.3) 4 (12.1) 7 (21.2) 33 (100)
Extra-gastrointestinal 17 (37.0) 4 (8.7) 16 (34.8) 9 (19.6) 46 (100)
Total 224 (32.0) 263 (37.6) 154 (22.0) 58 (8.3) 699 (100)
Mitosis ≥5
Esophagus 0 (0.0) 2 (40.0) 2 (40.0) 1 (20.0) 5 (100)
Stomach 23 (8.8) 112 (42.7) 77 (29.4) 50 (19.1) 262 (100)
Small intestine 11 (7.6) 34 (23.4) 62 (42.8) 38 (26.2) 145 (100)
Large intestine 7 (18.4) 9 (23.7) 16 (42.1) 6 (15.8) 38 (100)
Extra-gastrointestinal 9 (16.1) 7 (12.5) 16 (28.6) 24 (42.9) 56 (100)
Total 50 (9.9) 164 (32.4) 173 (34.2) 119 (23.5) 506 (100)
Table 5. Size distribution of all GISTs based on mitosis and location according to the new Miettinen criteria (2006)
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Fig. 1. Univariate survival analyses of varia-
bles: gender (A, P=0.026), age (B, P=0.006),
location (C, P=0.000), tumor size (D, P=
0.000) and mitosis (E, P=0.000) are signifi-
cantly correlated with patient’s survival.ed a higher mortality rate. 
All the variables except for smooth muscle actin immuno-
expression that was significantly correlated with the survival
were analyzed in this study with univariate analysis (Figs. 1-
4). In ages older than 60 yr, male gender, small intestinal and
extra-gastrointestinal location, larger than 10 cm in size, and
mitosis more than 5/50 HPF pointed to poor survival rate.
All histopathological variables analyzed in the study: mucos-
al and vessel invasions and necrosis were significantly related
with the survival (Fig. 2, P=0.000, P=0.000, and P=0.000,
respectively). Spindle cell type tumors showed a better prog-
nosis than mixed, epithelioid, and pleomorphic cell types
(Fig. 2, P=0.016). In the classification of GISTs by the NIH
criteria, there was no prognostically significant difference
between very low and low risk versus intermediate risk tumors,
but high-risk tumors pointed significantly to a shorter sur-
vival time (Fig. 4, P=0.000). According to the AFIP criteria,
the median survival time of malignant tumors was signifi-
cantly shorter than those of benign and uncertain malignan-
cy (Fig. 4, P=0.000). 
In multivariate analysis, tumor location, patient’s age, malig-
nant GISTs by the AFIP criteria, and stages of tumors showed
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Fig. 2. Univariate analysis of variables of microscopic findings: Tumor necrosis (A), vessel invasion (B), mucosal invasion (C) and histo-
logic type (D) are significantly correlated with patient’s survival (P=0.000, 0.000, 0.000, 0.016, respectively).
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Fig. 3. Univariate analysis of variables of immunohistochemical findings: CD34 expression (A) inversely relates with a patient’s survival
(P=0.001) in contrast to poor survival of GISTs with S-100 protein expression (B) (P=0.000). However a-smooth muscle actin expression
(C) is not correlated with patient’s survival (P=0.573). 
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Positive (n=351)significant correlation with the prognosis (Table 6). People
with tumor sizes more than 2 cm were more likely at an in-
creased risk of death compared to those with tumor sizes less
than 2 cm, but this data was statistically not significant (P=
0.247). In terms of tumor location, the risk was 1.985 and
2.423 times higher in small intestines and extra-gastrointesti-
nal than in stomachs (P=0.030 & 0.014), but the risk in large
intestinal GISTs was not higher (P=0.602). Malignant GISTs
by the AFIP criteria revealed a 6.211 times higher risk of
mortality compared with benign and borderline ones (P=
0.027). The risk in aggressive behavior of GISTs by the NIH
criteria slightly increased in intermediate tumors compared
with very low and low risk GISTs (odds ratio=0.443 & 0.585),
but this data was not statistically significant (P=0.524). GISTs
limited to organs revealed better survival of patients than
tumors, which invaded adjacent organs or metastasis. 
The immunoexpression of a-smooth muscle actin, CD34
and s-100 protein, necrosis, and mucosal and vascular inva-
sions were not available for multivariate analysis because of
the small number of results. 
As a result of this study, the GIST classifications based on
original tumor location together with size and mitosis is more
efficient than the NIH criteria in predicting patient’s survival.
However, the mechanism still needs to be clarified through
future studies. 
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Fig. 4. Univariate survival analysis of variables of diagnostic criterias: Both of the NIH criteria (A) and the AFIP criteria (B) are significantly
correlated with patient’s survival (P=0.000 & P=0.000).
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*P<0.05.
Variables P value Relative risk 95% C.I.
Size: <2 cm vs.  0.247
<5 cm 0.899 0.937 0.344-2.522
5-10 cm 0.507 1.370 0.540-3.478
>10 cm 0.139 2.043 0.793-5.261
Mitosis: <5 vs. ≥5 0.428 0.775 0.413-1.455
Location*: Stomach vs.
Small Intestine* 0.030* 1.958 1.066-3.595
Large intestine 0.602 1.313 0.472-3.657
Extra-gastrointestinal* 0.014* 2.423 1.199-4.897
Diagnosis by AFIP*
Benign & borderline vs. malignant 0.027* 6.211 1.210-29.603
Diagnosis by NIH: Very low & low risk vs. 0.524
Intermediate risk 0.325 0.443 0.088-2.240
High risk 0.548 0.585 0.102-3.366
Stage*: Confined to organs vs.
Invasion to adjacent organs 0.000* 4.133 2.062-8.281
Distant metastasis 0.001* 2.872 1.512-5.458
Recurrence 0.055 2.911 0.976-8.661
Gender 0.214 1.352 0.840-2.175
Age <60 vs. ≥60* 0.001* 2.340 1.385-3.952
Table 6. Multivariate analysis of eligible GISTs risk factors such as: size, mitosis, tumor location, diagnosis by AFIP criteira, diagnosis
by NIH criteria, gender and ageDISCUSSION
This is the first description of a population based on the
incidence of GISTs in Korea. In the review of the Korean NCI
Registry, we found a huge change regarding the incidences
of malignant GISTs between 1999-2002 and 2003-2005. For
example, the incidence of malignant GISTs in 2003 (0.69
per 100,000 population) was a double that of 2002 (0.24 per
100,000), even though there were no significant changes in
the incidences of all malignant tumors during the same time.
In regard with the change in incidences of GISTs, several his-
torical backgrounds may be related with them. The main
reasons of the incidence increase of GISTs during 2002-2005
in Korea is related to an improved understanding of patho-
biology, the treatment of GISTs, the introduction of schemat-
ic diagnostic criteria proposed by the NIH consensus work-
shop together with improved convenience of immunohisto-
chemical staining for c-KIT. Changes in the GIST incidences
similar to those in our study also has been described by Goettsch
et al. (16) and Steigen and Eide (17). 
Since the NIH publication, which was unfortunately based
on a consensus opinion rather than actual follow-up data (2),
numerous additional pathologic and biologic variables have
been evaluated as prognostic factors. In 2002 Miettien et al.
(18) analyzed a large AFIP series of GISTs coupled with long
term follow-up data and then proposed guidelines for the
evaluation of GISTs malignancies. Taking the Korean NCI
Registry in consideration, and including only tumors coded
as having malignant behavior, the incidence of all GISTs in
Korea can be estimated as 1.6 per 100,000 by the AFIP cri-
teria. The proportion of malignant GISTs by the AFIP crite-
ria was 43.1%. However, by the NIH criteria, the proportion
of high-risk GISTs was 32.1%, and the incidence of GISTs
was estimated 2.2 per 100,000. The incidence of GISTs have
been previously reported at 1-2 per 100,000 population by
Miettinen and Lastosa (3), 1.85-2.2 per 100,000 population
in the United States by Fletcher et al. (2), 2 per 100,000 pop-
ulation in southwestern Sweden by Nilsson et al. (9), and 1.1
per 100,000 population in Iceland by Tryggvason et al. (10).
The incidence of GIST in Korea did not appear to be differ-
ent from theirs. 
In the review of pathology reports, we found that most hos-
pitals in Korea used either the NIH criteria or the AFIP crite-
ria to predict the prognosis of GISTs. The results of our study,
different diagnostic criteria and terminology in two diagnos-
tic schemes, may have created some confusion in classifying
and estimating the incidence of GISTs. However, the iden-
tification of GISTs with poor prognosis is very important in
the choice of treatment modality to improve the survival. We
found a prognostic significance of the AFIP criteria in uni-
variate as well as multivariate analyses. In our previous report
on guideline for cancer registration, the intermediate and high
risk tumors were regarded as malignancy. However, the guide-
line is based on a consensus opinion rather than an actual fol-
low-up data (19). In this study, the prognosis of intermedi-
ate risk groups of GIST by the NIH criteria was not differ-
ent from those of the very low and low risk tumor groups
when follow-up data were examined. Previously published
reports also described no prognostic differences in interme-
diate risk GISTs and the very low and low risk ones (20). In
multivariate analysis of our study, the patients with interme-
diate and high risk GISTs were more likely to increase the
risk of mortality compared with very low and low risk GISTs,
but it was statistically not significant (P=0.325 and 0.548,
respectively). It appeared to be appropriate that only high-
risk tumors were regarded as malignant GISTs. However, a
few patients with low and intermediate risk tumors died of
diseases in our study. The prognosis of low and intermediate
risk GISTs by the NIH criteria remains to be clarified through
long term follow-up. The prognostic efficacy of the NIH cri-
teria has been discussed by several researchers (9, 21), and the
modification of the NIH criteria (20-22) was published recent-
ly to improve the risk-based stratification of GISTs. The orig-
inal NIH criteria adopted only tumor size and mitosis but
the significance of tumor size and location was considered on
AFIP criteria (12, 18). The impact of the location of GISTs
on the patient’s survival is still controversial. Some investiga-
tors demonstrated a more aggressive behavior in intestinal
GISTs than in gastric GISTs (9-12, 21, 23, 24), while oth-
ers found no differences in the patient’s survival (25). In the
results of our study, the AFIP criteria as well as the original
tumor location were prognostically significant in multivari-
ate analysis. There seems to be several explanations for prog-
nostic significances of the tumor location. Firstly, the prog-
nostic significance of the tumor location may be related to
early detection of gastric GISTs. This is supported by the fact
that gastric GISTs were significantly smaller than the non-
gastric ones (10). The results of our study demonstrated that
the malignant GISTs by the AFIP criteria or high risk by the
NIH criteria were far more common in the intestine and extra-
gastrointestinal than in the stomach at the time of diagno-
sis. Secondly, Miettinen et al. recently reported the true bio-
logic differences between gastric and non-gastric GISTs (26).
The mutation in exon 9 of the c-kit gene, which is related to
more aggressive tumors, was reported to be more frequently
found in small intestinal GISTs (24). Although Park et al. (25)
described that the tumor location was significant to predict
the overall survival of patients in univariate analysis of 93 high-
risk GISTs, but c-kit exon 9 mutations were not related with
poor prognosis in Korean patients. In the data of patients,
who died of the disease in our study, we found that the pro-
portion of intestinal and extra-gastrointestinal GISTs were
higher than gastric GISTs among the same categories by the
NIH criteria. This means that the anatomical tumor location
has to be related to a patient’s survival but it remains to be
clarified as to why. Furthermore, we found that three benign
and two uncertain malignant GISTs by the AFIP criteria had
mortality in this study. Therefore, further efforts to improve
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GISTs are needed. 
We found tumors with invasion or metastasis at the time
of diagnosis in 13.7%. As expected, the tumors, which were
confined to the original organs, revealed a better chance of
survival than tumors with local invasion or metastasis. Any
tumors showing metastatic lesion were classified into high
risk or malignant GISTs in this study. 
From the results of our study, we found several different
epidemiologic characteristics of GISTs in Korea. Male gen-
der was related with poor patient’s survival in univariate anal-
ysis, but not in multivariate analysis. Male gender has been
described as an independent adverse prognostic factor, (11)
but not fully consistent. The average patient’s age was 57.83
yr, and results in patients older than 60 yr indicated signifi-
cant poor survival rates. The patient’s age at the time of diag-
nosis has been described as a GIST prognosticator (11, 17,
21, 27). Extra-gastrointestinal tumors were found to be more
common than in previous reports. We found 8.3% of extra-
gastrointestinal malignant GISTs from the Korean NCI Reg-
istry and 10.1% of the data collected from 38 hospitals in
this study. However, the proportion was reported to be 5%
in previous reports (2). Extra-gastrointestinal GIST locations
were omentum, mesentery, pelvis, intra-abdominal, retroperi-
toneum, abdominal wall and pancreas in our study. All the
GISTs had been regarded as tumors with some malignant
potential, but this is being challenged by recent data reflect-
ing clinically insignificant and incidental GISTs. Microscopic
GISTs were detected during autopsies of the stomach in 23%
of patients older than 50 yr (28) and 35% of patients with
gastric carcinoma (29). Incidental GISTs were found during
operations of various diseases, but, except for the neurofibro-
matosis type 1 and Carney syndrome, no risk factors were
identified. During the course of our study, we incidentally
found GISTs in 8.2% and most commonly in the stomach
during surgery for gastric carcinoma, but in patients with
esophageal, colorectal, biliary tract, pancreatic, and hepato-
cellular carcinomas, gastrinoma, and ischemic colitis, GISTs
were rarely found.
We found the prognostic significance in the pathologic
findings of tumor necrosis and mucosal and vascular inva-
sions, but they were rarely described in the pathology reports.
From the results of this research, we recommend to describe
these prognostic factors in daily practice, even though it is
negative. We have three major limitations with regards to
data of this study. The first one is incomplete information of
chemotherapy. We reviewed the pathology reports with infor-
mation of surgery. The treatment modality was not consid-
ered for survival analysis in this study. The second limitation
is insufficient follow-up data. We analyzed the overall survival
time but not the recurrence of diseases. The follow-up dura-
tion in our study was less than 7 yr. The third one is from the
retrospective analysis of pathology reports. We could not ran-
domize the treatment modality. Even though these limita-
tions, we have concluded that the classification of GISTs based
on original tumor location together with size and mitosis is
more valuable to predict the prognosis. In addition, male gen-
der, age and stage should be considered as factors for risk strat-
ification of GISTs. Additionally, we recommend the descrip-
tion of the immunohistochemical results of CD34 and s-100
protein as well as histologic parameters such as tumor necro-
sis, mucosal and vascular invasions in pathology reports for
daily practice. 
Recently, many researchers focus on the significance of c-kit
and PDGFRA mutation in predicting the response to tyro-
sine kinase inhibitor therapy (30) and the correlation of res-
ponse to the therapy with type of c-kit mutation in GISTs
(13, 25). Because the biologic behavior of GISTs is different
in different locations and prognosis of low and intermediate
risk tumors is uncertain, the genetic analysis of GISTs might
be valuable, when assessing the prognosis of GISTs as well
as the efficacy of therapy.
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